sodium fluoride and Bone Cancer studies

Research Excerpts

Excerpt	Relevance	Reference
"The aim of this prospective study is to evaluate the diagnostic and prognostic usefulness of F-18 sodium fluoride (NaF) positron emission tomography-computed tomography (PET-CT) relative to Tc-99m methylene diphosphonate (MDP) planar bone scintigraphy with no CT (BS) for hepatocellular carcinoma (HCC) patients with suspicious bone metastasis."	9.14	The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. ( Chen, CY; Cheng, MF; Hong, RL; Shiau, YC; Wang, KL; Wu, K; Wu, YW; Yang, RS; Yen, RF; Yu, CJ, 2010)
"The purpose of the study was to compare the diagnostic accuracy and relative usefulness of MRI and 18 F-NaF (sodium fluoride) PET/computed tomography (CT) for detection of spinal bone metastases in a cohort of patients with high-risk breast cancer (BrCa)."	8.31	Review of the role of MRI and 18 F-sodium fluoride PET/computed tomography in the characterisation of spinal bone metastases in a cohort of patients with breast cancer. ( Panagiotidis, E; Pant, V; Vinjamuri, S, 2023)
"Sodium fluoride (Na-F) PET/CT is an imaging technique which allows radiolabeled fluoride to help detect areas of bone turnover."	6.52	Role of sodium fluoride PET imaging for identification of bony metastases in prostate cancer patients. ( Hughes, CT; Nix, JW, 2015)
"18F- Sodium Fluoride (NaF) is an excellent bone imaging agent used for skeletal staging but can also be localized in extra osseous calcifying lesions."	5.56	Incidental brain metastasis of breast cancer detected on 18F-Sodium Fluoride (NaF) PET-CT. ( Ahmed, N; Kandari, FA; Muzaffar, S; Usmani, S, 2020)
"F-sodium fluoride (NaF) is a bone-seeking agent that can also localize extraosseous calcifying lesions."	5.48	Unsuspected Metastases to Muscles in Osteosarcoma Detected on 18F-Sodium Fluoride PET-CT. ( Al Kandari, F; Al Maraghy, M; Bakiratharajan, D; Marafi, F; Rasheed, R; Usmani, S, 2018)
"A 73-year-old woman with breast cancer presented for restaging FDG PET/CT, which showed intense activity throughout almost the entire axial skeleton and no osseous metastases."	5.39	18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound. ( Avery, R; Kuo, PH, 2013)
"In a national prospective registry, we previously studied the impact of (18)F-sodium fluoride PET (NaF PET) on the intended management of cancer patients with osseous metastases."	5.20	18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. ( Duan, F; Hanna, L; Hillner, BE; Quinn, B; Shields, AF; Siegel, BA, 2015)
"The aim of this prospective study is to evaluate the diagnostic and prognostic usefulness of F-18 sodium fluoride (NaF) positron emission tomography-computed tomography (PET-CT) relative to Tc-99m methylene diphosphonate (MDP) planar bone scintigraphy with no CT (BS) for hepatocellular carcinoma (HCC) patients with suspicious bone metastasis."	5.14	The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. ( Chen, CY; Cheng, MF; Hong, RL; Shiau, YC; Wang, KL; Wu, K; Wu, YW; Yang, RS; Yen, RF; Yu, CJ, 2010)
"The purpose of the study was to compare the diagnostic accuracy and relative usefulness of MRI and 18 F-NaF (sodium fluoride) PET/computed tomography (CT) for detection of spinal bone metastases in a cohort of patients with high-risk breast cancer (BrCa)."	4.31	Review of the role of MRI and 18 F-sodium fluoride PET/computed tomography in the characterisation of spinal bone metastases in a cohort of patients with breast cancer. ( Panagiotidis, E; Pant, V; Vinjamuri, S, 2023)
"We compared the diagnostic accuracy of F-labeled sodium fluoride (F-NaF) PET-CT with 99m-technetium methylene diphosphonate (Tc-MDP) single photon emission computed tomography (SPECT) to detect bone metastases (BMs) in patients with preoperative lung cancer."	3.83	18F-Labeled NaF PET-CT in Detection of Bone Metastases in Patients With Preoperative Lung Cancer. ( Chen, Z; Rao, L; Shi, X; Wang, X; Yi, C; Zhang, X; Zong, Z, 2016)
"Patients with osteoblastic metastases from high risk osteosarcoma continue to have a poor prognosis after progression from standard-of-care multi-agent chemotherapy."	3.01	( Anderson, P; Kairemo, K; Macapinlac, HA; Rao, A; Ravizzini, G; Roszik, J; Subbiah, V, 2021)
"18F-Sodium fluoride is a bone tracer with a high signal-to-noise ratio, but its dosimetry is higher than that of 99mTc-labeled phosphonates at the recommended activities."	2.78	Can we achieve a radionuclide radiation dose equal to or less than that of 99mTc-hydroxymethane diphosphonate bone scintigraphy with a low-dose 18F-sodium fluoride time-of-flight PET of diagnostic quality? ( Balogova, S; Chauchat, P; Kerrou, K; Michaud, L; Nataf, V; Ohnona, J; Paycha, F; Talbot, JN, 2013)
"Sodium fluoride (Na-F) PET/CT is an imaging technique which allows radiolabeled fluoride to help detect areas of bone turnover."	2.52	Role of sodium fluoride PET imaging for identification of bony metastases in prostate cancer patients. ( Hughes, CT; Nix, JW, 2015)
"Newly diagnosed high-risk prostate cancer patients who underwent radical prostatectomy from 2011 to 2018."	1.72	Use of ( Mogensen, AW; Nørgaard, M; Pank, MT; Petersen, LJ; Torp-Pedersen, C; Zacho, HD, 2022)
"Two hundred consecutive prostate cancer patients who had undergone 68Ga-PSMA PET/CT and 18F-NaF PET/CT at baseline evaluation (n = 80) and following suspected recurrence or disease progression (restaging) (n = 120) were analyzed retrospectively."	1.72	Bone metastases in prostate cancer - Gallium-68-labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET/computed tomography - the better tracer? ( Agrawal, A; Bakshi, G; Choudhury, S; Joshi, A; Maitre, P; Menon, S; Mithun, S; Murthy, V; Natarajan, A; Noronha, V; Pal, M; Prabhash, K; Prakash, G; Purandare, N; Puranik, A; Rangarajan, V; Shah, S, 2022)
"Unexpectedly, breast cancer also revealed increased NaF activity."	1.56	18F-NaF Uptake in Breast Cancer. ( Chen, Y; Fu, W; Liu, H; Liu, L, 2020)
"18F- Sodium Fluoride (NaF) is an excellent bone imaging agent used for skeletal staging but can also be localized in extra osseous calcifying lesions."	1.56	Incidental brain metastasis of breast cancer detected on 18F-Sodium Fluoride (NaF) PET-CT. ( Ahmed, N; Kandari, FA; Muzaffar, S; Usmani, S, 2020)
"Patients with breast cancer, referred for F-NaF PET/CT between February 2014 and June 2016, were included in a database."	1.48	Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient management in patients with breast carcinoma. ( Broos, WAM; Knol, RJJ; van der Zant, FM; Wondergem, M, 2018)
"F-sodium fluoride (NaF) is a bone-seeking agent that can also localize extraosseous calcifying lesions."	1.48	Unsuspected Metastases to Muscles in Osteosarcoma Detected on 18F-Sodium Fluoride PET-CT. ( Al Kandari, F; Al Maraghy, M; Bakiratharajan, D; Marafi, F; Rasheed, R; Usmani, S, 2018)
"A cohort comprising of 13 patients with ESRD (mean age 65."	1.46	A proof-of-concept study analyzing the clinical utility of fluorine-18-sodium fluoride PET-CT in skeletal staging of oncology patients with end-stage renal disease on dialysis. ( Ahmed, N; Esmail, A; Marafi, F; Usmani, S, 2017)
"In 10 patients with breast cancer, skeletal tumour burden in pretreatment and post-treatment F-NaF PET/CT was compared with tumour marker and clinical evolution."	1.46	Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method. ( Costa, G; Iagaru, A; Lapa, P; Marques, M; Pedroso de Lima, J, 2017)
"Osteosarcoma is the most common bone sarcoma in adolescents and children."	1.43	Unusual Finding of a Tumor Thrombus Arising From Osteosarcoma Detected on 18F-NaF PET/CT. ( Agrawal, A; Purandare, N; Rangarajan, V; Shah, S; Verma, P, 2016)
"Sodium fluoride PET (18F-NaF) has recently reemerged as a valuable method for detection of osseous metastasis, with recent work highlighting the potential of coadministered 18F-NaF and 18F-FDG PET/CT in a single combined imaging examination."	1.42	Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone. ( Gambhir, SS; Iagaru, A; Lutz, AM; Mittra, ES; Mosci, C; Sampath, SC; Willmann, JK, 2015)
"A 73-year-old woman with breast cancer presented for restaging FDG PET/CT, which showed intense activity throughout almost the entire axial skeleton and no osseous metastases."	1.39	18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound. ( Avery, R; Kuo, PH, 2013)
"As bone metastases might be present in lung cancer despite a normal bone scan, we examined various alternatives prospectively."	1.32	F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. ( Arslandemir, C; Buck, AK; Gabelmann, A; Glatting, G; Hetzel, J; Hetzel, M; Hombach, V; König, HH; Nüssle, K; Schirrmeister, H, 2003)
"Aluminum fluoride (AlF(3)) was included for comparison."	1.31	Bone cell mitogenic action of fluoroaluminate and aluminum fluoride but not that of sodium fluoride involves upregulation of the insulin-like growth factor system. ( Arias, M; Baylink, DJ; Goodwin, C; Lau, KH; Mohan, S, 2002)
"Osteomas were first observed at Week 55."	1.29	Confounded carcinogenicity study of sodium fluoride in CD-1 mice. ( Anderson, RL; Boysen, BG; Cheng, MC; Maurer, JK; Seymour, JL; Squire, RA; Strandberg, JD; Weisbrode, SE, 1993)

Research

Studies (87)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Mean Heterogeneity of Response Across All Bone Lesions as Measured by Global Heterogeneity of NaF Standardized Uptake (SUVhetero) Score at Third 18F-NaF PET/CT Imaging (NaF-3) Schedule

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (4.60)	18.7374
1990's	7 (8.05)	18.2507
2000's	6 (6.90)	29.6817
2010's	51 (58.62)	24.3611
2020's	19 (21.84)	2.80

Authors	Studies
Kairemo, K	3
Roszik, J	1
Anderson, P	1
Ravizzini, G	1
Rao, A	1
Macapinlac, HA	1
Subbiah, V	2
Zacho, HD	3
Ravn, S	1
Ejlersen, JA	1
Fledelius, J	1
Dolliner, P	1
Nygaard, ST	1
Holdgaard, PC	1
Lauridsen, JF	1
Haarmark, C	1
Hendel, HW	2
Petersen, LJ	3
Mogensen, AW	1
Torp-Pedersen, C	1
Nørgaard, M	1
Pank, MT	1
Koa, B	1
Raynor, WY	3
Park, PSU	1
Borja, AJ	3
Singhal, S	1
Kuang, A	1
Zhang, V	1
Werner, TJ	5
Alavi, A	7
Revheim, ME	3
Bénard, F	1
Harsini, S	1
Wilson, D	1
Zukotynski, K	1
Abikhzer, G	2
Turcotte, E	1
Cossette, M	1
Metser, U	1
Romsa, J	1
Martin, M	1
Mar, C	1
Saad, F	1
Soucy, JP	1
Eigl, BJ	1
Black, P	1
Krauze, A	1
Burrell, S	1
Nichol, A	1
Tardif, JC	1
Agrawal, A	2
Natarajan, A	1
Mithun, S	1
Bakshi, G	1
Joshi, A	1
Murthy, V	1
Menon, S	1
Purandare, N	2
Shah, S	2
Puranik, A	1
Choudhury, S	1
Prakash, G	1
Pal, M	1
Maitre, P	1
Prabhash, K	1
Noronha, V	1
Rangarajan, V	2
Panagiotidis, E	2
Pant, V	1
Vinjamuri, S	3
Rocha, NH	1
Zacchi, SR	1
Sado, HN	2
Buchpiguel, CA	2
Duarte, PS	2
Sapienza, MT	2
Puri, T	1
Frost, ML	1
Moore, AEB	1
Choudhury, A	1
Mahajan, A	1
Fynbo, C	1
Vrist, M	1
Theil, J	1
Wong, J	1
Zaidi, H	1
Cook, GJR	1
Blake, GM	1
Ahuja, K	1
Sotoudeh, H	1
Galgano, SJ	1
Singh, R	1
Gupta, N	1
Gaddamanugu, S	1
Choudhary, G	1
Ueda, CE	1
de Castroneves, LA	1
Flávio, J	1
Marin, G	1
Hoff, AO	1
Liu, H	1
Liu, L	1
Fu, W	1
Chen, Y	1
Khaw, TH	1
Al-Zaghal, A	1
Jonnakuti, VS	1
Cheng, N	1
Houshmand, S	2
Xiao, J	1
Wang, D	1
Guo, B	1
Wang, L	1
Su, M	1
Xu, H	1
Kyriakopoulos, CE	1
Heath, EI	1
Ferrari, A	1
Sperger, JM	1
Singh, A	1
Perlman, SB	3
Roth, AR	2
Perk, TG	3
Modelska, K	1
Porcari, A	1
Duggan, W	1
Lang, JM	1
Jeraj, R	6
Liu, G	5
Usmani, S	7
Ahmed, N	6
Ilyas, MW	1
Murad, S	1
Al Kandari, F	4
Muzaffar, S	1
Kandari, FA	1
Hancin, EC	1
Morland, D	1
Godard, F	1
Lalire, P	1
Eymard, JC	1
Papathanassiou, D	1
Lapa, P	2
Saraiva, T	1
Silva, R	1
Marques, M	2
Costa, G	2
Lima, JP	1
Marafi, F	5
Esmail, A	4
Van den Wyngaert, T	3
Woodhead, GJ	1
Avery, RJ	1
Kuo, PH	2
Wondergem, M	2
van der Zant, FM	2
Knol, RJJ	2
Burgers, AMG	1
Bos, SD	1
de Jong, IJ	1
Pruim, J	1
Dyrberg, E	1
Larsen, EL	1
Thomsen, HS	1
Broos, WAM	1
Lam, K	1
Mistry, A	1
Seshadri, N	1
Al Nuaimi, M	1
Gnanasegaran, G	2
Rasheed, R	1
Bakiratharajan, D	1
Al Maraghy, M	1
Weisman, AJ	1
Harmon, SA	3
Eickhoff, J	2
Choyke, PL	2
Kurdziel, KA	2
Dahut, WL	2
Humm, JL	1
Apolo, AB	2
Larson, SM	1
Morris, MJ	2
Perk, T	1
Bradshaw, T	1
Chen, S	1
Im, HJ	1
Cho, S	1
Perlman, S	2
Wang, WL	1
Zhou, J	1
Gou, Z	1
Wu, R	1
Yuan, Y	1
Yu, G	1
Zhao, Y	1
Høilund-Carlsen, PF	2
Iagaru, A	6
Young, P	1
Mittra, E	2
Dick, DW	2
Herfkens, R	1
Gambhir, SS	3
Cuccurullo, V	1
Cascini, GL	1
Tamburrini, O	1
Rotondo, A	1
Mansi, L	1
Ohnona, J	1
Michaud, L	1
Balogova, S	2
Paycha, F	2
Nataf, V	2
Chauchat, P	1
Talbot, JN	2
Kerrou, K	2
Avery, R	1
Ouvrier, MJ	1
Vignot, S	1
Thariat, J	1
Derlin, T	1
Clauditz, TS	1
Bannas, P	1
Oldan, JD	1
Kuzminski, S	1
James, O	1
Mick, CG	1
James, T	1
Hill, JD	1
Williams, P	1
Perry, M	1
Simoncic, U	1
Staab, MJ	1
Straus, JE	1
Sampath, SC	2
Mosci, C	2
Lutz, AM	1
Willmann, JK	1
Mittra, ES	2
Sabbah, N	1
Jackson, T	1
Jamali, M	1
Minamimoto, R	1
Quon, A	1
Hillner, BE	1
Siegel, BA	1
Hanna, L	1
Duan, F	1
Quinn, B	1
Shields, AF	1
Koo, PJ	1
David Crawford, E	1
Hughes, CT	1
Nix, JW	1
Chan, HP	1
Hu, C	1
Yu, CC	1
Huang, TC	1
Peng, NJ	1
Piccardo, A	1
Puntoni, M	1
Morbelli, S	1
Massollo, M	1
Bongioanni, F	1
Paparo, F	1
Altrinetti, V	1
Gonella, R	1
Gennari, A	1
Iacozzi, M	1
Sambuceti, G	1
DeCensi, A	1
Rowe, SP	1
Mana-Ay, M	1
Javadi, MS	1
Szabo, Z	1
Leal, JP	1
Pomper, MG	1
Pienta, KJ	1
Ross, AE	1
Gorin, MA	1
Verma, P	1
Rao, L	1
Zong, Z	1
Chen, Z	1
Wang, X	1
Shi, X	1
Yi, C	1
Zhang, X	1
Guo, HH	1
Moradi, F	1
Raynor, W	1
Gholami, S	1
Emamzadehfard, S	1
Rajapakse, CS	1
Blomberg, BA	1
Baker, JF	1
Ashamalla, M	1
Koutroumpakis, E	1
McCarthy, L	1
Hegener, P	1
Grimm, R	1
Mehdi, S	1
Srour, S	1
Fried, G	1
Drumea, K	1
Kozlener, E	1
Frenkel, A	1
Israel, O	1
Fogelman, I	1
Kagna, O	1
Tuite, MJ	1
Pedroso de Lima, J	1
Roop, MJ	1
Singh, B	1
Singh, H	1
Watts, A	1
Kohli, PS	1
Mittal, BR	1
Singh, G	1
Kairemo, KJ	1
Hockley, BG	1
Scott, PJ	1
Yen, RF	1
Chen, CY	1
Cheng, MF	1
Wu, YW	1
Shiau, YC	1
Wu, K	1
Hong, RL	1
Yu, CJ	1
Wang, KL	1
Yang, RS	1
Czernin, J	1
Satyamurthy, N	1
Schiepers, C	1
Langsteger, W	1
Huchet, V	1
Beheshti, M	1
Egrot, C	1
Janetschek, G	1
Loidl, W	1
Pascal, O	1
Cussenot, O	1
Tarnawska-Pierścińska, M	1
Hołody, Ł	1
Braziewicz, J	1
Królicki, L	1
Brunkhorst, T	1
Boerner, AR	1
Bergh, S	1
Otto, D	1
Gratz, FW	1
Knapp, WH	1
Hetzel, M	1
Arslandemir, C	1
König, HH	1
Buck, AK	1
Nüssle, K	4
Glatting, G	2
Gabelmann, A	1
Hetzel, J	1
Hombach, V	1
Schirrmeister, H	5
Grant, FD	1
Fahey, FH	1
Packard, AB	1
Davis, RT	1
Treves, ST	1
Cohen, HJ	1
Silberman, HR	1
Tornyos, K	1
Bartolucci, AA	1
Huaux, JP	1
Noël, H	1
Bastien, P	1
Doyen, C	1
Nagant de Deuxchaisnes, C	1
Shupe, JL	1
Eanes, ED	1
Leone, NC	1
Gruber, HE	1
Stauffer, ME	1
Thompson, ER	1
Baylink, DJ	2
Włodarski, PK	1
Włodarski, KH	1
Galus, K	1
Skarpetowski, AC	1
Kowalski, M	1
Luczak, M	1
Marciniak, MM	1
Maurer, JK	1
Cheng, MC	1
Boysen, BG	1
Squire, RA	1
Strandberg, JD	1
Weisbrode, SE	1
Seymour, JL	1
Anderson, RL	1
Kotzerke, J	3
Rentschler, M	2
Träger, H	3
Fenchel, S	1
Diederichs, CG	1
Reske, SN	4
Guhlmann, CA	1
Elsner, K	2
Guhlmann, A	2
Neumaier, B	1
Buck, A	1
Hashimoto, H	1
Lau, KH	2
Goodwin, C	1
Arias, M	1
Mohan, S	1
Mongiorgi, R	1
Bertocchi, G	1
Gnudi, S	1
Maggi, G	1
Moroni, A	1
Coppola, G	1
Riva di Sanseverino, L	1
Banting, DW	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
18F- Sodium Fluoride PET Imaging as a Replacement for Bone Scintigraphy[NCT01930812]	Phase 3	286 participants (Actual)	Interventional	2014-07-31	Completed
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÏVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER[NCT02384382]	Phase 2	23 participants (Actual)	Interventional	2015-11-30	Completed
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases[NCT00375830]	Phase 2	114 participants (Actual)	Interventional	2006-01-31	Completed
Pharmacodynamic Response Assessment With PET/MRI Imaging in Patients With Metastatic Prostate CAncer to Bone Treated With ZD4054[NCT01119118]	Phase 2	6 participants (Actual)	Interventional	2010-04-30	Terminated
The National Oncologic PET Registry[NCT00868582]		333,000 participants (Anticipated)	Observational	2006-05-31	Active, not recruiting
The Effectiveness of Whole-body 18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer: A Comparison Study With 99mTc-MDP Bone Scintigraphy.[NCT00414934]		100 participants (Anticipated)	Observational	2006-10-31	Recruiting
A Pilot Study of F-18 Sodium Fluoride PET/CT for Metastatic Burden Qualification in Prostate Cancer[NCT01240551]	Phase 2	60 participants (Actual)	Interventional	2010-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Global SUVhetero score:Sum of(SUVmean of each lesion minus global SUVmean of all lesion)^2/number of lesions,measure of heterogeneity of tumor activity across all bone lesions.SUVmean(mean NaF uptake)indicated average activity of each lesions.Real limits for SUVhetero score ranged:0(minimum) to infinite(maximum).Higher global SUVhetero score:more heterogeneity in bone lesion activity.NaF-3 performed on any of these 1)PSA progression(increase of>=25% and absolute increase of>=2.0ng/mL above nadir);2)bone PD(appearance of>=2 new lesions after screening assessed by 99mTc-MDP bone scintigraphy);3)soft tissue PD(RECIST1.1);4)clinically relevant progression by investigator;5)at 2years without progression after treatment initiation.PD perRECIST1.1:>=20%increase in sum of diameters of target lesions,(reference smallest sum on study,this included baseline sum if that is smallest on study),relative increase of20%,sum of diameters indicated absolute increase of>=5mm,appearance of>=1 new lesions. (NCT02384382)
Timeframe: At NaF-3 schedule: at time of PSA, or radiographic(bone or soft tissue), or clinically relevant progression, or at 2years without progression after treatment initiation, whichever occurred first(From first dose of study drug up to maximum of 34.1 months)

Percentage of Participants With at Least (>=) 1 Responding Bone Lesion Assessed by Total Sodium Fluoride (NaF) Standardized Uptake Value [SUVtotal] at Third 18F-NaF PET/CT Imaging (NaF-3) Schedule

Intervention	unit on SUVhetero score (Mean)
Enzalutamide 160 mg (18F-NaF PET/CT)	3.9

Bone lesion responded: if its change from baseline in SUVtotal is below limit of agreement (LOA, no specific value, based upon test/retest analysis using software). SUVtotal: total NaF uptake,indicated tumor burden across all bone lesions/in individual lesions reflecting bone-metastatic prostate cancer.NaF-3 performed on any of these: 1) prostate-specific antigen (PSA) progression(increase of >=25% and absolute increase of >=2.0 ng/mL above nadir); 2) bone progressive disease(PD)(appearance of >=2 new lesions after screening assessed by technetium Tc 99m medronate [99mTc-MDP] bone scintigraphy); 3) soft tissue PD; 4) clinically relevant progression by investigator; 5) at 2 years without progression after treatment initiation. PD, RECIST1.1:>=20% increase in sum of diameters of target lesions,(reference smallest sum on study, included baseline sum if that is smallest on study),relative increase of 20%,sum of diameters indicated absolute increase of >=5mm, appearance of >=1 new lesions. (NCT02384382)
Timeframe: At NaF-3 schedule: at time of PSA, or radiographic(bone or soft tissue), or clinically relevant progression, or at 2years without progression after treatment initiation, whichever occurred first(From first dose of study drug up to maximum of 34.1 months)

Cohort 3 - Skeletal Lesions Identified by 99mTc MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI

Intervention	percentage of participants (Number)
Enzalutamide 160 mg (18F-NaF PET/CT)	100.0

Participants in Cohort 3 received 99mTc-methylene diphosphonate (MDP) whole-body bone scintigraphy (WBBS) and 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / magnetic imaging resonance (PET/MRI) scans. On the basis of the scans, participants with skeletal lesions were identified. The outcome is reported as the number of Cohort 3 participants for whom skeletal lesions were identified by each scan methodology, a number without dispersion. (NCT00375830)
Timeframe: 30 days

Cohort 3 - Total Skeletal Lesions Identified, Tc-99m MDP WBBS vs 18F-NaF / 18F-FDG PET/MRI

Intervention	Participants (Count of Participants)
Cohort 3 - 99mTc-methyl Diphosphonate (MDP) Bone Scan	37
Cohort 3 - 18F-NaF / 18F-FDG PET/MRI	45

Participants in Cohort 3 received 99mTc-methylene diphosphonate (MDP) whole-body bone scintigraphy (WBBS) and 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / magnetic imaging resonance (PET/MRI) scans. On the basis of the scans, the total number skeletal lesions identified in the participants was determined. The outcome is reported as the total number skeletal lesions identified by each scan methodology, a number without dispersion. (NCT00375830)
Timeframe: 30 days

Cohort 1 - 18F-NaF PET/CT vs 18F-FDG PET/CT

Intervention	lesions (Number)
Cohort 3 - 99mTc-methyl Diphosphonate (MDP) Bone Scan	81
Cohort 3 - 18F-NaF / 18F-FDG PET/MRI	140

The medical value of 18F-sodium fluoride (NaF) positron emission tomography / computed tomography (PET/CT) vs 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) was assessed on the basis of the radiation oncologist's medical assessment of image quality and detected extent of disease, for each participant diagnosed with osseous (skeletal) metastases. Per protocol, the data were collected and the outcome is reported for Cohort 1 only. The outcome is reported as the number of participants for whom the medical value of the image was superior for 18-NaF PET/CT compared to 18F-FDG PET/CT, the same between both scans, or inferior for 18-NaF PET/CT compared to 18F-FDG PET/CT. The outcome result is represented as a number without dispersion. (NCT00375830)
Timeframe: 30 days

Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy

Intervention	Participants (Count of Participants)
	18F-NaF > 18F-FDG	18F-NaF = 18F-FDG	18F-NaF < 18F-FDG
Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET Scans	3	0	0

"The medical value of 18F-sodium fluoride (NaF) positron emission tomography / computed tomography (PET/CT) vs 99mTc-methylene diphosphonate (MDP) bone scintigraphy was assessed on the basis of the radiation oncologist's medical assessment of image quality and detected extent of disease, for each participant. Per protocol, the data were collected and the outcome is reported for Cohort 1 only. The outcome is reported as the number of participants for whom the medical value of the image was superior for 18F-NaF vs 99mTc-MDP bone scintigraphy (18F-NaF > 99mTc-MDP), the same between both scans (18F-NaF = 99mTc-MDP), or inferior for 18F-NaF vs 99mTc-MDP bone scintigraphy (18F-NaF < 99mTc-MDP)." (NCT00375830)
Timeframe: 30 days

Cohort 2 - 18F-NaF/18F-FDG PET/CT vs Whole-body MRI for Detection of Extraskeletal Lesions

Intervention	Participants (Count of Participants)
	18F-NaF > 99mTc-MDP	18F-NaF = 99mTc-MDP	18F-NaF < 99mTc-MDP
Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET Scans	10	0	0

"Sensitivity; positive predictive value (PPV); and accuracy for the detection of extraskeletal lesions was assessed for 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) and for whole body magnetic imaging resonance (WB-MRI).~Sensitivity is a percentage that defines the proportion of true positive participants with the disease in a total group of participants.~PPV is the probability that participants with a positive screening test truly have the disease.~Accuracy is the proportion of true results (both true positives and true negatives) among the total number of cases examined.~Per protocol, the data were collected and the outcome is reported for Cohort 2 only. Sensitivity, PPV, and accuracy are reported as a percentage, a number without dispersion. Higher numbers represent better detection." (NCT00375830)
Timeframe: 30 days

Cohort 2 - 18F-NaF/18F-FDG vs 99mTc-MDP Bone Scintigraphy for Detection of Skeletal Lesions

Intervention	percentage of particpants (Number)
	Sensitivity	Positive predictive value	Accuracy
Cohort 2 - Combined 18F-NaF-CT/18F-FDG-PET Scan	92.9	81.3	76.5
Cohort 2 - Whole Body-MRI Scan	92.9	86.7	82.4

Sensitivity and accuracy for the detection of skeletal lesions was assessed for 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) and for 99mTc-methylene diphosphonate (MDP) bone scintigraphy. Per protocol, the data were collected and the outcome is reported for Cohort 2 only. Sensitivity and accuracy are reported as a percentage, a number without dispersion. Higher numbers represent better detection. (NCT00375830)
Timeframe: 30 days

Cohort 2 - 18F-NaF/18F-FDG vs Whole-body MRI for Detection of Skeletal Lesions

Intervention	percentage of participants (Number)
	Sensitivity	Accuracy
Cohort 2 - 99mTc-MDP Bone Scintigraphy Scan	64.6	65.9
Cohort 2 Combined 18F-NaF-CT/18F-FDG-PET Scan	96.2	89.8

Sensitivity and accuracy for the detection of skeletal lesions was assessed for 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) and for whole body magnetic imaging resonance (WB-MRI). Per protocol, the data were collected and the outcome is reported for Cohort 2 only. Sensitivity and accuracy are reported as a percentage, a number without dispersion. Higher numbers represent better detection. (NCT00375830)
Timeframe: 30 days

Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI

Intervention	percentage of particpants (Number)
	Sensitivity	Accuracy
Cohort 2 - Combined 18F-NaF-CT/18F-FDG-PET Scan	96.2	89.8
Cohort 2 - WB-MRI Scan	81.4	74.7

Overall sensitivity and accuracy for the detection of tumor lesions was assessed for 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) and for whole body magnetic imaging resonance (WB-MRI). Per protocol, the data were collected and the outcome is reported for Cohort 2 only. Sensitivity and accuracy are reported as a percentage, a number without dispersion. Higher numbers represent better detection. (NCT00375830)
Timeframe: 30 days

Cohort 2 - Overall Sensitivity and Accuracy for 18F-NaF/18F-FDG vs Whole-body MRI/99mTc-MDP Bone Scintigraphy

Intervention	percentage of participants (Number)
	Sensitivity	Accuracy
Cohort 2 - Combined 18F-NaF-CT/18F-FDG-PET Scan	95.7	87.6
Cohort 2 - Whole Body Magnetic Resonance Imaging (WB-MRI) Scan	83.3	76.0

Overall sensitivity and accuracy for the detection of tumor lesions was assessed for 18F-sodium fluoride (NaF) / 18F-fluorodeoxyglucose (FDG) positron emission tomography / computed tomography (PET/CT) and for 99mTc-methylene diphosphonate (MDP) bone scintigraphy. Per protocol, the data were collected and the outcome is reported for Cohort 2 only. Sensitivity and accuracy are reported as a percentage, a number without dispersion. Higher numbers represent better detection. (NCT00375830)
Timeframe: 30 days

Number of Subjects Whose Tumor Lesion Size Changed Using Iterative Decomposition of Water and Fat With Echo Asymmetry and Least-squares Estimation (IDEAL)-MRI Imaging Alone

Number of Subjects With PSA Response

The Number of Subjects Whose Tumor Lesion Size Changed After 6 Weeks of Treatment With ZD4054 Using PET and MRI Scans.

Intervention	percentage of participants (Number)
	Sensitivity	Accuracy
Cohort 2 Combined 18F-NaF-CT/18F-FDG-PET Scan	95.7	87.6
Cohort 2 WB-MRI & 99mTc-MDP Bone Scintigraphy	91.6	83.0

Intervention	participants (Number)
ZD4054	0

Intervention	participants (Number)
ZD4054	0

Multimodal Positron Emission Tomography (PET) and Magnetic Resonant Imaging (MRI) imaging were used to evaluate changes in the tumor lesion size following 6 weeks of treatment with ZD4054. (NCT01119118)
Timeframe: Week 6

The Number of Subjects Whose Tumor Lesion Size Changed Using Diffusion-weighted Imaging (DWI)-Magnetic Resonant Imaging (MRI) Alone

The Number of Subjects Whose Tumor Lesion Size Changed Using Positron Emission Tomography (PET) Imaging Alone.

Number of Participants With Adverse Events

Intervention	participants (Number)
ZD4054	0

Intervention	participants (Number)
ZD4054	0

Intervention	participants (Number)
ZD4054	0

Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT01240551)
Timeframe: date treatment consent signed to date off study, approximately 52.5 months

Number of Participants With Present or Not Present Bone Metastasis

Intervention	Participants (Count of Participants)
Mets Via NaF-18 PET/CT	1
No-Mets Via NaF-18 PET/CT	1

Present and not present bone metastasis was determined by sodium fluoride (NaF) PET (positron emission imaging)/CT (computed tomography) imaging. Present bone metastasis is defined as greater than normal bone uptake. Not present bone metastasis is defined as physiological bone uptake of F-18 NaF on PET/CT imaging (i.e. excluding traumatic and degenerative foci of increased F-18 NaF uptake. (NCT01240551)
Timeframe: Single imaging sessions will be acquired at baseline, between 4-6 months and between 10-12 months on emolument.

Article	Year
Feasibility of Global Assessment of Bone Metastases in Prostate Cancer with PET clinics, 2022, Volume: 17, Issue:4 Topics: Alkaline Phosphatase; Bone Neoplasms; Feasibility Studies; Fluorine Radioisotopes; Humans; Male; Pos	2022
Utility of a simplified [ Frontiers in endocrinology, 2023, Volume: 14 Topics: Bone and Bones; Bone Neoplasms; Humans; Positron Emission Tomography Computed Tomography; Positron-E	2023
Journal of nuclear medicine technology, 2020, Volume: 48, Issue:1 Topics: Bone and Bones; Bone Neoplasms; Diphosphonates; Feasibility Studies; Fluorine Radioisotopes; Humans;	2020
Novel Musculoskeletal and Orthopedic Applications of PET clinics, 2021, Volume: 16, Issue:2 Topics: Bone Neoplasms; Fluorine Radioisotopes; Humans; Male; Positron Emission Tomography Computed Tomograp	2021
Skeletal Metastases and Benign Mimics on NaF PET/CT: A Pictorial Review. AJR. American journal of roentgenology, 2018, Volume: 211, Issue:1 Topics: Bone Neoplasms; Diagnosis, Differential; Fluorine Radioisotopes; Humans; Neoplasm Staging; Positron	2018
The clinical significance of incidental soft tissue uptake on whole body Clinical radiology, 2019, Volume: 74, Issue:2 Topics: Bone Neoplasms; Fluorine Radioisotopes; Humans; Organs at Risk; Positron Emission Tomography Compute	2019
Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis. Skeletal radiology, 2019, Volume: 48, Issue:12 Topics: Bone Neoplasms; Choline; Gallium Isotopes; Gallium Radioisotopes; Humans; Magnetic Resonance Imaging	2019
Bone metastases radiopharmaceuticals: an overview. Current radiopharmaceuticals, 2013, Volume: 6, Issue:1 Topics: 3-Iodobenzylguanidine; Bone Neoplasms; Choline; Dihydroxyphenylalanine; Diphosphonates; Fluorine Rad	2013
[State of the art in nuclear imaging for the diagnosis of bone metastases]. Bulletin du cancer, 2013, Volume: 100, Issue:11 Topics: Bone Neoplasms; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Lung Neo	2013
Molecular imaging in oncology: (18)F-sodium fluoride PET imaging of osseous metastatic disease. AJR. American journal of roentgenology, 2014, Volume: 203, Issue:2 Topics: Bone Neoplasms; Fluorine Radioisotopes; Humans; Positron-Emission Tomography; Radiopharmaceuticals;	2014
¹⁸F-NaF PET/CT and ¹¹C-Choline PET/CT for the initial detection of metastatic disease in prostate cancer: overview and potential utilization. Oncology (Williston Park, N.Y.), 2014, Volume: 28, Issue:12 Topics: Bone Neoplasms; Carbon Radioisotopes; Choline; Fluorine Radioisotopes; Humans; Male; Multimodal Imag	2014
Role of sodium fluoride PET imaging for identification of bony metastases in prostate cancer patients. Current urology reports, 2015, Volume: 16, Issue:5 Topics: Bone Neoplasms; Early Detection of Cancer; Humans; Male; Neoplasm Metastasis; Positron-Emission Tomo	2015
Evolving Role of Molecular Imaging with (18)F-Sodium Fluoride PET as a Biomarker for Calcium Metabolism. Current osteoporosis reports, 2016, Volume: 14, Issue:4 Topics: Arthritis, Rheumatoid; Back Pain; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone and Bones	2016
PET/Computed Tomography for Radiation Therapy Planning of Prostate Cancer. PET clinics, 2017, Volume: 12, Issue:2 Topics: Bone Neoplasms; Brachytherapy; Fluorine Radioisotopes; Gallium Radioisotopes; Humans; Male; Neoplasm	2017
Molecular mechanisms of bone 18F-NaF deposition. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:12 Topics: Animals; Bone and Bones; Bone Diseases; Bone Neoplasms; Cyclotrons; Drug Compounding; Fluorine Radio	2010
Bone metastases diagnosis possibilities in studies with the use of 18F-NaF and 18F-FDG. Nuclear medicine review. Central & Eastern Europe, 2011, Volume: 14, Issue:2 Topics: Bone Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging;	2011
Skeletal PET with 18F-fluoride: applying new technology to an old tracer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008, Volume: 49, Issue:1 Topics: Bone and Bones; Bone Neoplasms; Fluorine Radioisotopes; Humans; Positron-Emission Tomography; Radiop	2008
Diagnosis of bone disease by core biopsies. Seminars in hematology, 1981, Volume: 18, Issue:4 Topics: Adult; Aged; Biopsy; Bone and Bones; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Female; Humans	1981
[Positron emission tomography of the skeletal system using 18FNa: frequency, distribution and appearance of skeletal metastases]. Rontgenpraxis; Zeitschrift fur radiologische Technik, 1999, Volume: 52, Issue:1 Topics: Bone Neoplasms; Contrast Media; Humans; Neoplasm Metastasis; Sodium Fluoride; Tomography, Emission-C	1999

Article	Year
Current problems in cancer, 2021, Volume: 45, Issue:5 Topics: Adolescent; Adult; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans; Lung Neoplasms; Neoplasm	2021
Intra-individual comparison of The Lancet. Oncology, 2022, Volume: 23, Issue:12 Topics: Bone Neoplasms; Breast Neoplasms; Canada; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging;	2022
Exploring Spatial-Temporal Changes in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-01, Volume: 38, Issue:31 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Flu	2020
Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clinical nuclear medicine, 2013, Volume: 38, Issue:7 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hum	2013
Can we achieve a radionuclide radiation dose equal to or less than that of 99mTc-hydroxymethane diphosphonate bone scintigraphy with a low-dose 18F-sodium fluoride time-of-flight PET of diagnostic quality? Nuclear medicine communications, 2013, Volume: 34, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Diphosphonates; Female; Fluorine Rad	2013
18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:2 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Female; Fluorodeoxygl	2015
Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors. Physics in medicine and biology, 2016, 10-21, Volume: 61, Issue:20 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Algorithms; Benchmarking; Bone Neoplasms; Feasibility Studi	2016
Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer. Clinical nuclear medicine, 2017, Volume: 42, Issue:5 Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F1	2017
The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nuclear medicine communications, 2010, Volume: 31, Issue:7 Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Fluorine Radioisotop	2010
Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Molecular imaging and biology, 2012, Volume: 14, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F	2012
Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood, 1984, Volume: 63, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcium Gluconate; Carmustine; Clini	1984
Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1999, Volume: 40, Issue:10 Topics: Bone Neoplasms; False Negative Reactions; Fluorine Radioisotopes; Humans; Lung Neoplasms; Magnetic R	1999

Article	Year
Observer experience and accuracy of 18F-sodium-fluoride PET/CT for the diagnosis of bone metastases in prostate cancer. Nuclear medicine communications, 2022, Jun-01, Volume: 43, Issue:6 Topics: Bone Neoplasms; Fluorides; Fluorine Radioisotopes; Humans; Male; Positron Emission Tomography Comput	2022
Use of BMJ open, 2022, 06-15, Volume: 12, Issue:6 Topics: Bone Neoplasms; Cohort Studies; Fluorine Radioisotopes; Humans; Male; Positron-Emission Tomography;	2022
Bone metastases in prostate cancer - Gallium-68-labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET/computed tomography - the better tracer? Nuclear medicine communications, 2022, Dec-01, Volume: 43, Issue:12 Topics: Bone Neoplasms; Fluorine; Gallium Radioisotopes; Humans; Male; Positron Emission Tomography Computed	2022
Review of the role of MRI and 18 F-sodium fluoride PET/computed tomography in the characterisation of spinal bone metastases in a cohort of patients with breast cancer. Nuclear medicine communications, 2023, 03-01, Volume: 44, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Female; Fluorine Radioisotopes; Hu	2023
Comparison of Oral and IV 18 F-NaF PET/CT Administration in the Assessment of Bone Metastases in Patients With Breast or Prostate Cancers. Clinical nuclear medicine, 2023, Sep-01, Volume: 48, Issue:9 Topics: Bone Neoplasms; Fluorine Radioisotopes; Humans; Male; Positron Emission Tomography Computed Tomograp	2023
Reply: Off-Target Report on Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019, Volume: 60, Issue:12 Topics: Bone Neoplasms; Fluorine Radioisotopes; Humans; Male; Positron Emission Tomography Computed Tomograp	2019
Burden of metastatic bone disease measured on 18F-NaF PET/computed tomography studies as a prognostic indicator in patients with medullary thyroid cancer. Nuclear medicine communications, 2020, Volume: 41, Issue:5 Topics: Adult; Bone Neoplasms; Carcinoma, Neuroendocrine; Female; Fluorine Radioisotopes; Humans; Male; Midd	2020
18F-NaF Uptake in Breast Cancer. Clinical nuclear medicine, 2020, Volume: 45, Issue:11 Topics: Biological Transport; Bone Neoplasms; Breast Neoplasms; Female; Fluorine Radioisotopes; Humans; Midd	2020
Assessing the effects of body weight on subchondral bone formation with quantitative Annals of nuclear medicine, 2020, Volume: 34, Issue:8 Topics: Aged; Aged, 80 and over; Body Weight; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans; Male;	2020
Observer agreement and accuracy of 18F-sodium fluoride PET/computed tomography in the diagnosis of skull-base bone invasion and osseous metastases in newly diagnosed nasopharyngeal carcinoma. Nuclear medicine communications, 2020, Volume: 41, Issue:9 Topics: Adult; Aged; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Nasopharynge	2020
Rare Thyroid Cartilage Metastasis From Breast Cancer Visualized on 18F-NaF PET/CT. Clinical nuclear medicine, 2021, Volume: 46, Issue:1 Topics: Aged; Bone Neoplasms; Breast Neoplasms; Female; Fluorine Radioisotopes; Humans; Laryngeal Neoplasms;	2021
Incidental brain metastasis of breast cancer detected on 18F-Sodium Fluoride (NaF) PET-CT. JPMA. The Journal of the Pakistan Medical Association, 2020, Volume: 70, Issue:10 Topics: Adult; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Female; Fluorine Radioisotopes; Humans; Po	2020
Superiority of NaF PET/CT Over Chest CT in a Case of Osteosarcoma. Clinical nuclear medicine, 2021, Jul-01, Volume: 46, Issue:7 Topics: Bone Neoplasms; Fluorine Radioisotopes; Humans; Male; Neoplasm Metastasis; Osteosarcoma; Positron Em	2021
[Superiority of 18F-FNa PET/CT for Detecting Bone Metastases in Comparison with Other Diagnostic Imaging Modalities]. Acta medica portuguesa, 2017, Jan-31, Volume: 30, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Choline; Female; Fluorodeoxyglucose F18;	2017
Diagnostic Challenge of Staging Metastatic Bone Disease in the Morbidly Obese Patients: A Primary Study Evaluating the Usefulness of 18F-Sodium Fluoride (NaF) PET-CT. Clinical nuclear medicine, 2017, Volume: 42, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans; Male; Middle	2017
A proof-of-concept study analyzing the clinical utility of fluorine-18-sodium fluoride PET-CT in skeletal staging of oncology patients with end-stage renal disease on dialysis. Nuclear medicine communications, 2017, Volume: 38, Issue:12 Topics: Aged; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans; Kidney Failure, Chronic; Male; Neoplas	2017
Atlas of Extraosseous Findings Detected by 18F-NaF PET/CT Bone Scan. Clinical nuclear medicine, 2017, Volume: 42, Issue:12 Topics: Aged; Biological Transport; Bone and Bones; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans;	2017
World journal of urology, 2018, Volume: 36, Issue:1 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Cohort Studies; Diphosphonates; Fluorine Radioisotopes; Hum	2018
Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT. Acta radiologica (Stockholm, Sweden : 1987), 2018, Volume: 59, Issue:9 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Choline; Humans; Magnetic Resonance Imaging; Male; Middle A	2018
Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient management in patients with breast carcinoma. Nuclear medicine communications, 2018, Volume: 39, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Female; Fluorine Radioisotopes; Fo	2018
Technical feasibility, radiation dosimetry and clinical use of Annals of nuclear medicine, 2018, Volume: 32, Issue:9 Topics: Adolescent; Bone Neoplasms; Child; Child, Preschool; Female; Fluorine Radioisotopes; Humans; Infant;	2018
Unsuspected Metastases to Muscles in Osteosarcoma Detected on 18F-Sodium Fluoride PET-CT. Clinical nuclear medicine, 2018, Volume: 43, Issue:9 Topics: Adult; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans; Muscle, Skeletal; Osteosarcoma; Posit	2018
Quantification of bone flare on Prostate cancer and prostatic diseases, 2019, Volume: 22, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Fluorine Radioisotopes; Humans; Male	2019
Automated classification of benign and malignant lesions in Physics in medicine and biology, 2018, 11-20, Volume: 63, Issue:22 Topics: Algorithms; Automation; Bone Neoplasms; Fluorine Radioisotopes; Humans; Image Processing, Computer-A	2018
Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology. BMJ case reports, 2019, Apr-23, Volume: 12, Issue:4 Topics: Adult; Bone Neoplasms; Cell Transformation, Neoplastic; Diagnosis, Differential; Female; Fluorodeoxy	2019
Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 2019, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Bone Neoplasms; Fluorine Radioisotopes; Humans; Male; Positron Emission Tomog	2019
Off-Target Report on Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019, Volume: 60, Issue:12 Topics: Bone Neoplasms; Fluorine Radioisotopes; Humans; Male; Positron Emission Tomography Computed Tomograp	2019
18F sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound. Clinical nuclear medicine, 2013, Volume: 38, Issue:9 Topics: Aged; Bone Neoplasms; Breast Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Huma	2013
Glioblastoma multiforme metastastic to the bone: diagnosis by (18)F-NaF PET/CT. Clinical nuclear medicine, 2014, Volume: 39, Issue:2 Topics: Adult; Bone Neoplasms; Fluorine Radioisotopes; Glioblastoma; Humans; Male; Multimodal Imaging; Posit	2014
Ivory vertebra on 18F-sodium fluoride scan: an old sign in a new modality. Clinical nuclear medicine, 2014, Volume: 39, Issue:11 Topics: Aged; Bone Neoplasms; Fluorine Radioisotopes; Humans; Male; Positron-Emission Tomography; Prostatic	2014
Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clinical genitourinary cancer, 2015, Volume: 13, Issue:1 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Clinical Trials, Phase III as Topic; Fluorodeoxyglucose F18	2015
Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone. Clinical nuclear medicine, 2015, Volume: 40, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle	2015
18F-sodium fluoride PET/CT in oncology: an atlas of SUVs. Clinical nuclear medicine, 2015, Volume: 40, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans; Male; Middle	2015
Added value of using a cocktail of F-18 sodium fluoride and F-18 fluorodeoxyglucose in positron emission tomography/computed tomography for detecting bony metastasis: a case report. Medicine, 2015, Volume: 94, Issue:13 Topics: Bone Neoplasms; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Im	2015
18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. Nuklearmedizin. Nuclear medicine, 2015, Volume: 54, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Neoplasms; Breast Neoplasms; Female; Fluorodeoxyglu	2015
PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT? Clinical genitourinary cancer, 2016, Volume: 14, Issue:1 Topics: Antigens, Surface; Bone Neoplasms; Glutamate Carboxypeptidase II; Humans; Lysine; Male; Middle Aged;	2016
Unusual Finding of a Tumor Thrombus Arising From Osteosarcoma Detected on 18F-NaF PET/CT. Clinical nuclear medicine, 2016, Volume: 41, Issue:6 Topics: Adolescent; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans; Osteosarcoma; Positron Emission	2016
18F-Labeled NaF PET-CT in Detection of Bone Metastases in Patients With Preoperative Lung Cancer. Medicine, 2016, Volume: 95, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplas	2016
Clinical significance of extraskeletal computed tomography findings on 18F-NaF PET/CT performed for osseous metastatic disease evaluation. Nuclear medicine communications, 2016, Volume: 37, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Female; Fluorine Radioisotopes; Humans; Incidental F	2016
Osseous Sarcoidosis Mimicking Metastatic Cancer on Positron Emission Tomography. Journal of oncology practice, 2016, Volume: 12, Issue:7 Topics: Bone Diseases; Bone Neoplasms; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Lipo	2016
Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer. Nuclear medicine communications, 2016, Volume: 37, Issue:11 Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Female; Fluorine Radioisotopes; Humans; Middle Aged;	2016
Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method. Nuclear medicine communications, 2017, Volume: 38, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Female; Fluorine Radio	2017
An automated method for preparation of [(18)F]sodium fluoride for injection, USP to address the technetium-99m isotope shortage. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2010, Volume: 68, Issue:1 Topics: Automation; Bone Neoplasms; Fluorine Radioisotopes; Isotope Labeling; Positron-Emission Tomography;	2010
Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2011, Volume: 55, Issue:4 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Choline; Fluorine Radioisotopes; Humans; Male; Middle Aged;	2011
Pretherapeutic assessment of tumour metabolism using a dual tracer PET technique. European journal of nuclear medicine and molecular imaging, 2002, Volume: 29, Issue:10 Topics: Adolescent; Bone Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neo	2002
F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2003, Volume: 18, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Cost-Benefit Analysis; Decision Trees; Female; Fluor	2003
[Bony lesions in hairy cell leukemia. Various therapeutic considerations apropos of a case report]. Acta clinica Belgica, 1984, Volume: 39, Issue:6 Topics: Adult; Bone Neoplasms; Diphosphonates; Humans; Leukemia, Hairy Cell; Lymphokines; Male; Osteoclasts;	1984
Effect of excessive exposure to sodium fluoride on composition and crystallinity of equine bone tumors. American journal of veterinary research, 1981, Volume: 42, Issue:6 Topics: Animals; Bone and Bones; Bone Neoplasms; Exostoses, Multiple Hereditary; Fluorides; Horse Diseases;	1981
In vivo exposure to sodium fluoride does not modify the yield of viral tumour-induced periosteal bone nor of heterotopic bone induced by human tumour KB cells in mice. Folia biologica, 1995, Volume: 41, Issue:2 Topics: Animals; Bone and Bones; Bone Neoplasms; Cell Transformation, Viral; Female; Humans; KB Cells; Male;	1995
Confounded carcinogenicity study of sodium fluoride in CD-1 mice. Regulatory toxicology and pharmacology : RTP, 1993, Volume: 18, Issue:2 Topics: Animals; Bone Neoplasms; Carcinogens; Female; Male; Mice; Mice, Inbred ICR; Osteoma; Parainfluenza V	1993
[Positron-emission tomography of the skeletal system using 18FNa: the incidence, pattern of the findings and distribution of benign changes]. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1998, Volume: 169, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Diseases; Bone Neoplasms; Diagnosis, Differenti	1998
Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid : official journal of the American Thyroid Association, 2001, Volume: 11, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Neoplasms; Female; Fluorine Radioisotopes; Huma	2001
Differential effects of bacterial toxins on mitogenic actions of sodium fluoride and those of aluminum fluoride in human TE85 osteosarcoma cells. Molecular and cellular biochemistry, 2001, Volume: 228, Issue:1-2 Topics: Alkaline Phosphatase; Aluminum Compounds; Bone Neoplasms; Cell Division; Cholera Toxin; Fluorides; H	2001
Bone cell mitogenic action of fluoroaluminate and aluminum fluoride but not that of sodium fluoride involves upregulation of the insulin-like growth factor system. Bone, 2002, Volume: 30, Issue:5 Topics: Aluminum; Aluminum Compounds; Bone Neoplasms; Cell Division; DNA; Fluorides; Fluorine; Gene Expressi	2002
Influence of the fluoride ion in the stability of bone hydroxyapatite achieved in patients after the fluo-calcic therapy. Bollettino della Societa italiana di biologia sperimentale, 1991, Volume: 67, Issue:4 Topics: Bone and Bones; Bone Neoplasms; Fluorides; Humans; Microscopy, Electron, Scanning; Multiple Myeloma;	1991
The future of fluoride. An update one year after the National Toxicology Program Study. Journal of the American Dental Association (1939), 1991, Volume: 122, Issue:8 Topics: Animals; Bone Neoplasms; Female; Fluoridation; Fluorosis, Dental; Fractures, Bone; Humans; Male; Mic	1991

sodium fluoride and Bone Cancer